Hanwha Chemical has selected Emerson Process Management to supply and commission its DeltaV™ digital automation system for a pharmaceutical production facility in Osong Bio-technology Technopolis, Chungcheongbuk-do, South Korea
Emerson Automation Solutions
+1 (512) 834-7214
DeltaV system will automate manufacturing process and facilitate rapid commercialization of product for high consumer growth sector
AUSTIN, TEXAS (September 15, 2011) -- Hanwha Chemical has selected Emerson Process Management to supply and commission its DeltaV™ digital automation system for a pharmaceutical production facility in Osong Bio-technology Technopolis, Chungcheongbuk-do, South Korea. Known as the Eagle Project, the facility will manufacture Hanwha’s biosimilar rheumatoid arthritis drug HD203. The DeltaV system will play a key role in automating the facility’s biotechnology process and support the compliance requirements for FDA approval. Project completion is planned for 2012.
Hanhwa Chemical has led the South Korean petrochemical industry for more than four decades. Biomedicine is a new business sector through which Hanhwa aims to become a global leader specializing in antibody production. Hanwha’s HD203 is the biosimilar of Enbrel, which has been a top-selling biomedicine. Sales of such medicines are expected to continue growing due to rapid market acceptance and increasing demand from an aging society.
“The project is truly meaningful for both Hanhwa Chemical and Emerson,” said Yi Gil-seon, plant manager of Eagle Project, Hanwha Chemical. “Emerson has proven experience in automating biotechnology processes and meeting regulatory compliance requirements. The DeltaV system provides functionality that reduces wiring and decreases site construction costs by using Electronic Marshalling panels. This solution will help reduce construction time by as much as half, which will facilitate the rapid commercialization the product.”
“Equipment and system reliability is the most important aspect in a bio-process,” Yi continued. “Only a completely proven facility is allowed to produce a drug directly administered into the human body. Emerson’s proven validation capability was therefore the most critical aspect of our system selection.”
The 2,900-I/O Eagle Project will consolidate its plant process using an integrated system of Emerson’s DeltaV S-Series, AMS Suite asset management software, and audit/change control functionality that supports validation requirements.
Emerson will provide a total of 34 Electronic Marshalling panels, 10 operator workstations installed in the clean room process areas, five manager workstations, and five server stations. The server stations will be used for the process historical data collection, alarm management, complete batch control, and diagnosis of the engineering and control systems.
Process package equipment will be integrated via Profibus DP / MODBUS / OPC communication and the status of all the I/O and devices will be monitored to assess their operating condition.
Emerson’s Electronic Marshalling will not only reduce the site construction time and cost, but also provide a complete solution for future I/O expansion and plant management, because it can be installed in the proximity of devices in the process area and provide the ultimate in flexibility – allowing users to choose I/O type on a channel by channel basis.
Emerson’s AMS Suite asset management software will be used during installation of measurement and control devices to help reduce costs and improve device startup efficiency. On an ongoing basis, AMS Suite will further increase the availability and performance of the plant by providing online access to instrument and valve predictive diagnostic information and automatic documentation of field device maintenance.
The DeltaV digital automation system helps improve process manufacturing operations by harnessing today's predictive technologies in an easy, intuitive, and interoperable way to connect people, processes, and production. To learn more about the DeltaV system, go to www.deltav.com.